AR041386A1 - Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias - Google Patents

Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias

Info

Publication number
AR041386A1
AR041386A1 ARP030103484A ARP030103484A AR041386A1 AR 041386 A1 AR041386 A1 AR 041386A1 AR P030103484 A ARP030103484 A AR P030103484A AR P030103484 A ARP030103484 A AR P030103484A AR 041386 A1 AR041386 A1 AR 041386A1
Authority
AR
Argentina
Prior art keywords
composition
ssri
corticosteroid
treatment
inhibitor
Prior art date
Application number
ARP030103484A
Other languages
English (en)
Spanish (es)
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041386(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of AR041386A1 publication Critical patent/AR041386A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
ARP030103484A 2002-09-24 2003-09-24 Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias AR041386A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
AR041386A1 true AR041386A1 (es) 2005-05-18

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103484A AR041386A1 (es) 2002-09-24 2003-09-24 Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias

Country Status (12)

Country Link
EP (1) EP1553955A4 (de)
JP (1) JP2006503905A (de)
AR (1) AR041386A1 (de)
AU (1) AU2003299196A1 (de)
BR (1) BR0314713A (de)
CA (1) CA2509526A1 (de)
HR (1) HRP20050355A2 (de)
IS (1) IS7811A (de)
MX (1) MXPA05003152A (de)
NO (1) NO20051669L (de)
TW (1) TW200422042A (de)
WO (1) WO2004030618A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MXPA06003320A (es) * 2003-09-24 2006-06-08 Combinatorx Inc Regimenes terapeuticos para administrar combinaciones de farmacos.
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
US20080255074A1 (en) * 2004-11-19 2008-10-16 N.V. Organon Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression
KR101355422B1 (ko) * 2005-04-13 2014-02-06 아스션 팔마 에이/에스 피부 결합조직질환 치료용 베타-2 아드레노리셉터 작용제
JP4832806B2 (ja) * 2005-06-03 2011-12-07 久光製薬株式会社 経皮投与製剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
ES2376493T3 (es) * 2006-09-08 2012-03-14 Ore Pharmaceuticals Inc. Procedimiento para reducir o aliviar la inflamación en el tubo digestivo.
WO2008033754A2 (en) * 2006-09-11 2008-03-20 Duke University Xanthine derivatives in methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
PT117765A (pt) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa Formulação tópica de fluvoxamina para o tratamento de psoríase
TW202423434A (zh) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 mTOR抑制劑的點眼劑微懸液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230862T2 (de) * 1991-10-15 2000-12-14 Michael F. Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
ES2259746T3 (es) * 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
BR0314713A (pt) 2005-07-26
NO20051669L (no) 2005-06-10
WO2004030618A2 (en) 2004-04-15
TW200422042A (en) 2004-11-01
EP1553955A2 (de) 2005-07-20
CA2509526A1 (en) 2004-04-15
WO2004030618A3 (en) 2005-04-07
HRP20050355A2 (en) 2005-10-31
EP1553955A4 (de) 2008-11-05
JP2006503905A (ja) 2006-02-02
IS7811A (is) 2005-04-19
MXPA05003152A (es) 2006-04-27
AU2003299196A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
AR041386A1 (es) Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias
Riedel et al. Age, APOE and sex: triad of risk of Alzheimer’s disease
Urani et al. The antidepressant-like effect induced by ς1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test
EP2282778B1 (de) Neue therapeutische ansätze zur behandlung von alzheimer-krankheit und verwandter erkrankungen durch modulation der angiogenese
Netzer et al. Lowering β-amyloid levels rescues learning and memory in a Down syndrome mouse model
RU2006112587A (ru) Способы и средства для лечения иммуновоспалительных нарушений
Koepsell General overview of organic cation transporters in brain
Reddy et al. Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer’s disease
McKallip et al. Plumbagin-induced apoptosis in lymphocytes is mediated through increased reactive oxygen species production, upregulation of Fas, and activation of the caspase cascade
Shimamoto et al. Sex-dependent mental illnesses and mitochondria
WO2011053876A1 (en) The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
CA2732440C (en) Cystamine analogues for the treatment of parkinson`s disease
WO2008118423A1 (en) Compositions and methods for treating medical conditions
EP4126235A2 (de) Identifizierung und verwendung von verbindungen bei der behandlung oder prävention von schweren akuten atemwegssyndrom-coronavirus 2
Yang et al. Exposure to a mixture of per-and polyfluoroalkyl substances modulates pulmonary expression of ACE2 and circulating hormones and cytokines
Hinoi et al. Characterization with [3H] quisqualate of group I metabotropic glutamate receptor subtype in rat central and peripheral excitable tissues
Go et al. NQO1 regulates pharmaco-behavioral effects of d-amphetamine in striatal dopaminergic system in mice
ZA200604250B (en) Methods and reagents for the treatment of inflammatory disorders
Heintz Role of Cyp2b in Unsaturated Fatty Acid Metabolism, Obesity, and Non-Alcoholic Fatty Liver Disease
US9410938B2 (en) Biomarkers for asthma
RU2005112233A (ru) Способы и реагенты для лечения заболеваний и нарушений, связанных с повышенными уровнями провоспалительных цитокинов
Nguyen Sex differences in stress responsivity, glucocorticoid signaling, and disease
Kambarova et al. Biochemical and genetic aspects of pathogenesis of schizophrenia
Sabale Liver kinase B1 modulation of tau expression and phosphorylation
Doerfler et al. Deletion of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Promotes Expansion of the Resident Stem Cell Compartment

Legal Events

Date Code Title Description
FB Suspension of granting procedure